Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.
|Number of pages||7|
|Publication status||Published or Issued - May 2018|
- Cardiovascular risk
- Clinical trials
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine